Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLX1B-SULT1A4 readthrough is a naturally occurring chimeric transcript resulting from transcriptional read-through between the adjacent SLX1B and SULT1A4 genes on chromosome 16. It is recognized as a candidate for nonsense-mediated mRNA decay and is unlikely to result in production of a protein product or to possess a functional role. The constituent genes, SLX1B and SULT1A4, respectively encode an endonuclease subunit and a phenol-preferring sulfotransferase enzyme, but the read-through transcript itself is not considered a therapeutic target[1][2][4][8].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SLX1B-SULT1A4 readthrough (SLX1B-SULT1A4).